miR-24-3p Is Antiviral Against SARS-CoV-2 by Downregulating Critical Host Entry Factors

Area of Science:

• Virology
• Molecular Biology
• RNA Therapeutics

Background:

• Emerging SARS-CoV-2 variants pose a continuous threat to existing therapies.
• Multi-target inhibition strategies, successful in treating HIV and HCV, offer a model for combating viral escape mutants.
• RNA-based therapeutics, particularly microRNAs, are gaining traction due to their manufacturing ease and therapeutic potential.

Purpose of the Study:

• To identify and characterize novel microRNAs with broad-spectrum antiviral activity against SARS-CoV-2 and other coronaviruses.
• To investigate the mechanism of action of promising microRNA candidates, focusing on their impact on viral entry, replication, and production.
• To evaluate the efficacy of identified microRNAs against common SARS-CoV-2 escape mutations.

Main Methods:

• Bioinformatic analysis to predict microRNA targets involved in coronavirus infection.
• Experimental validation of microRNA-mediated inhibition of viral entry factors (furin, NRP1, NRP2, SREBP2).
• Assessment of microRNA efficacy against SARS-CoV-2 and HCoV-229E, including mutant strains.

Main Results:

• miR-24-3p was identified as a potent inhibitor of SARS-CoV-2 entry, replication, and virion production.
• miR-24-3p demonstrated retained efficacy against common SARS-CoV-2 mutations.
• The study confirmed that miR-24-3p directly downregulates key host entry factors, including furin, NRP1, NRP2, and SREBP2.
• Comparative analysis with HCoV-229E supported the broad applicability of the miR-24-3p mechanism.

Conclusions:

• miR-24-3p represents a promising therapeutic candidate for treating SARS-CoV-2 infections.
• Its ability to target multiple host factors suggests potential efficacy against current and future emerging coronaviruses.
• This research highlights the therapeutic potential of microRNAs in combating viral diseases with high mutation rates.